Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31662531 | 0.84 | PIK3CD (0.35) | MEN1HTTKMT2ACA14ACACB | |
| SCHEMBL20428869 | 0.84 | SLC6A2 (0.35) | TSHRMEN1HTTKMT2ACA14 | |
| SCHEMBL16467209 | 0.81 | CYP19A1 (0.43) | MEN1HTTKMT2ASMN1; SMN2EPHX1 | |
| SCHEMBL16467167 | 0.80 | CYP19A1 (0.45) | HTTSMN1; SMN2EPHX1ALDH1A1RAB9A | |
| SCHEMBL20288706 | 0.75 | SLC6A3 (0.42) | TSHRMEN1HTTKMT2AALDH1A1 | |
| SCHEMBL20288867 | 0.75 | SLC6A3 (0.42) | TSHRMEN1HTTKMT2AALDH1A1 | |
| SCHEMBL3670044 | 0.74 | LMNA (0.43) | TSHRMEN1HTTKMT2ASMN1; SMN2 | |
| SCHEMBL14759200 | 0.73 | EPHX1 (0.33) | MEN1HTTKMT2AEPHX1 | |
| SCHEMBL14759131 | 0.71 | EPHX1 (0.35) | EPHX1ALDH1A1 | |
| SCHEMBL445678 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143263-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2012-03-27 | — | — | US | disclosed |
| US-20100093757-A1 | THERAPEUTIC AGENTS 414 | ASTRAZENECA AB (SE) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093757-A1 | THERAPEUTIC AGENTS 414 | GCK, GCKR, GPR119 | TSHR 1264/4885MEN1 2410/4885HTT 2010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.